RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer
unknown📝 Article Content
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM , Sept. 06, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) significantly reduces the development of epidermal growth factor receptor (EGFR)- and MET-driven resis
📄 Summary
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM , Sept. 06, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) significantly reduces the development of epidermal growth factor receptor (EGFR)- and MET-driven resis